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Blockade of CD40-CD40 ligand protects against renal injury
in chronic proteinuric renal disease.
Background. Interaction between CD40 and CD40 ligand
(CD40L) is involved in both cognate and innate immune re-
sponses. Blockade of CD40-CD40L interactions reduces sever-
ity of renal injury in murine lupus nephritis and membranous
nephropathy. We hypothesized that CD40-CD40L could con-
tribute to renal injury in models that are not antibody-depen-
dent, and that anti-CD40L could diminish inflammation and
fibrosis in murine adriamycin nephropathy.
Methods. Male BALB/c mice were divided into three groups
(N  6 per group): (1) saline-treated, age-matched control;
(2) adriamycin only; and (3) MR1  adriamycin. In group 3,
mice were treated with intraperitoneal injections of anti-
CD40L antibody (clone MR1, 0.4 mg per mouse) after the
onset of proteinuria at days 5, 7, 9, and 11 after adriamycin
treatment. Animal subgroups were compared at 14 and 42 days
after induction of adriamycin nephropathy. Functional and
pathologic markers of disease severity, cellular components of
interstitial inflammation, and the degree of CD40 expression
were assessed. Relative cortical RNA expression of the chemo-
kine monocyte-chemoattractant protein-1 (MCP-1) and regu-
lated on activation normal T cell expressed and secreted
(RANTES) was also compared between animal groups.
Results. CD40 was weakly expressed in tubules of normal
mice but was expressed in tubules, interstitium, and glomeruli
of mice with adriamycin nephropathy in a time-dependent man-
ner. MR1 treatment resulted in a significant attenuation of the
severity of adriamycin nephropathy at day 42 [e.g., glomerular
sclerosis (%), group 3, 20.1  4.7 vs. group 2, 30.2  7.2, P 
0.001]. CD40L blockade significantly reduced tubulointerstitial
injury as well [tubular diameter (m), group 3, 42.5  6.9 vs.
group 2, 66.3  13.7, P  0.001; and group 1, 37.3  5.7, P 
0.01; tubular cell height (m), group 3, 16.3  1.7 vs. group 2,
11 1.8, P 0.01; and group 1, 18.2 1.9, P 0.01; interstitial
volume (%), group 3, 13.9  5.1 vs. group 2, 26.2  4.9, P 
0.001; and group 1, 1.3  0.7, P  0.001; proteinuria (mg/24
hours), group 3, 1.8  0.6 vs. group 2, 4.3  0.8, P  0.001;
and group 1, 0.7  0.2, P  0.05; and creatinine clearance (L/
min), group 3, 75  4 vs. group 2, 35  2, P  0.001; and
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group 1, 82  4, P  0.01] were also improved by MR1. MR1
treatment also resulted in a significant reduction in the number
of cortical macrophages at both 14 and 42 days after adriamycin
(P  0.01). Cortical expression of MCP-1 and RANTES was
significantly reduced by MR1 treatment at 42 days after adria-
mycin (P  0.01 and P  0.05, respectively).
Conclusion. Blockade of CD40-CD40L interaction protects
against renal structural and functional injury in this murine
model of chronic proteinuric renal disease.
Tubulointerstitial inflammation is a consistent feature
of chronic renal disease, regardless of the initiating insult.
Parenchymal injury as a result of this inflammation is
believed to contribute to the functional and pathologic
changes observed. Proinflammatory effects of CD40 and
CD40 ligand (CD40L) interaction are one of many fac-
tors involved in the initiation and maintenance of this
inflammatory response and as such form a potential tar-
get for therapy.
Understanding of the biological role of CD40-CD40L
interactions (reviewed in [1]) is in a state of evolution.
CD40 was initially described as a transmembrane protein
on B lymphocytes [2] with a role in the activation of
humoral immunity [3]. Subsequent studies have demon-
strated constitutive and inducible CD40 expression on
a large number of other cells, including mononuclear,
dendritic, endothelial, and epithelial cells [1]. Not sur-
prisingly, therefore, CD40-dependent effects on the im-
mune system extend beyond B-lymphocyte activation.
Ligation of CD40 upon other cell types induces a broad
proinflammatory response, including the production of
a number of proinflammatory cytokines and adhesion
molecules. Of direct relevance to renal diseases, ligation
of tubular cell CD40 in vitro resulted in the production
of various inflammatory cytokines, including interleukin
(IL)-1, IL-6, IL-8, IL-15, IL-17, monocyte-chemoattrac-
tant protein-1 (MCP-1) and regulated on activation nor-
mal T cell expressed and secreted (RANTES) [4–6]. In a
similar manner, although binding of CD40 to membrane-
associated CD40L on T lymphocytes is a crucial “co-
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stimulatory” signal for antigen recognition, it is now rec-
ognized that the soluble cytokine-like form of CD40L
[which belongs to the tumor-necrosis factor (TNF) su-
perfamily] is capable of inducing CD40-dependent re-
sponses remote from the site of its production [7].
CD40L blockade has previously been shown to be
protective in animal models of glomerular disease that
are dependent upon the production of autoantibodies,
namely murine lupus [8] and membranous nephritis [9].
In light of the effects of CD40-CD40L interaction that
extend beyond B-cell–dependent responses, we hypothe-
sized that CD40-CD40L interactions may also have a
pathogenic role in adriamycin nephrosis. Renal injury in
adriamycin nephrosis is not autoantibody dependent and
indeed it appears that B lymphocytes play a minimal
role [10].
MATERIALS
Animals
BALB/c mice, 8 weeks old and weighing around 24 g,
were supplied by the Animal Care Facility, Westmead
Hospital, Sydney, Australia. All animals were housed in
standard conditions and allowed free access to standard
food and water. Each animal subgroup consisted of six
to seven mice.
Experimental design
Mice were divided into three groups: (1) normal con-
trol; (2) adriamycin-alone; and (3) MR1  adriamycin.
A model of chronic glomerular disease was induced as
previously described. Murine adriamycin nephropathy
was induced as previously described [10] by a single
intravenous injection of adriamycin (9.6 mg/kg). Control
animals were treated with an equivalent intravenous vol-
ume of saline vehicle.
The hamster anti-CD40L antibody (clone MR1, 0.4 mg
per mouse) was purified by protein G chromatography
from the culture supernatant of an immunoglobulin G
(IgG)-producing hybridoma [11]. In the MR1  adria-
mycin group, mice were given 0.4 mg of MR1 antibody
at days 5, 7, 9, and 11 after adriamycin treatment. The
timing of MR1 treatment was designed to occur after the
induction of proteinuria in this model [10]. Adriamycin-
alone animals were given an equivalent amount of mu-
rine IgG.
Animal subgroups were anaesthetized and sacrificed
on days 14 and 42 after adriamycin. Blood samples were
collected by cardiac puncture and both kidneys were
removed for various analyses. A group of four normal
mice was injected four times with same amount of MR1
antibody for examination of the possibility that antibody
per se causes renal injury, and none of them had any
histologic injury.
Another group in our department tested efficacy of the
anti-CD40L antibody. A dose of 500 g of MR1 antibody
given intraperitoneally on days 0, 2, 4 and 6 prolonged
survival of islet xenografts to 66 days and with cytotoxic
T-lymphocyte associated antigen-4 (CTLA4)-Fc treat-
ment produced indefinite graft survival [12]. These data
demonstrated that this dose of MR1 antibody effectively
blocked CD40-CD40L interaction. The same batch and
dose of MR1 antibody was used in the present studies.
Renal functional assay
Fasting animals were placed in metabolic cages for 12
hours to collect urine for determination of urinary pro-
tein and creatinine. Creatinine clearance was calculated
as creatinine excretion divided by plasma creatinine con-
centration. Venous blood for serum creatinine and albu-
min was collected at the time of sacrifice.
Histologic assessment
At week 6, the kidney was removed and weighed. A
coronal slice was fixed in 10% neutral-buffered formalin
for 24 hours and then dehydrated in graded alcohols and
embedded in paraffin. Tissues were cut at 5m and stained
with hematoxylin and eosin, periodic acid-Schiff (PAS),
and Masson’s trichrome. The degree of glomerulosclero-
sis was measured using a quantitative method [13].
Images viewed under a light microscope were digital-
ized using a video camera and then transferred onto a
computer screen (Tang Computer, Sydney, Australia)
using image analysis software (Optimas, version 5, Media
Cybernetics, Seattle, WA, USA). The outline of the glo-
merular capillary tuft was traced, and the computed area
was used as a measure of total glomerular area. The area
covered by PAS-positive staining in the same glomerulus
was then determined. The percentage of glomeruloscle-
rosis was calculated by dividing the total PAS-positive
area by the total glomerular area. The mean value of 20
randomly selected glomeruli was determined for each
section. The degree of interstitial expansion was deter-
mined by quantitation of the relative interstitial volume.
Random cortical fields were viewed at a magnification
of 200. The percentage relative interstitial volume was
calculated from the area occupied by trichrome-stained
interstitium divided by the total area. The mean value
of five cortical fields was determined for each section.
To avoid selection bias [13], the areas to be viewed for
morphometric analysis were anatomically identical for
each section and positioned prior to microscopic visual-
ization. Tubular atrophy was defined by the finding of a
tubule with dilated tubular lumen and low cell height
with absence of brush border.
Immunohistochemistry
Coronal slices of kidneys were embedded in 22-oxycal-
citriol (OCT) compound (Tissue-Tek; Sakura Finetek,
Torrance, CA, USA), frozen in liquid nitrogen, and
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Table 1. Sequence of upstream and downstream murine primers used for reverse transcription-polymerase chain reaction (RT-PCR) analysis
Primer Sequence cDNA position
MCP-1 Forward 5-GCT-TCA-GAT-TTA-CGG-GTC-AA-3 43-443
Reverse 5-CAC-TCA-GAT-TTA-CGG-GTC-AA-3
RANTES Forward 5-CTG-CTG-CTT-TGC-CTA-CCT-CT-3 146-432
Reverse 5-GCC-CAT-TTT-CCC-AGG-AC-3
18sRNA Forward 5-GCG-GCG-GCG-TTA-TTC-C-3 1103-1268
Reverse 5-GGT-GAG-GTT-TCC-CGT-GTT-GA-3
Abbreviations are: MCP-1, monocyte chemoattractant protein-1; RANTES, regulated on activation normal T cell expressed and secreted.
stored at –70C. Frozen sections were cut at 5 m, fixed
with acetone at 4C for 15 minutes, and blocked with 5%
normal rabbit serum to minimize nonspecific antibody
binding. Sections were incubated with antibodies against
murine macrophages (1:100, clone F4/80; Serotec, Ox-
ford, UK), murine CD4 (1:100, clone RM4-5; BD Biosci-
ences, San Diego, CA, USA), murine CD8 (1:100, clone
53-6.7; BD Biosciences), and murine CD40 (1:10, clone
3/23; BD Biosciences) for 60 minutes at room tempera-
ture. After washing in phosphate-buffered saline (PBS),
the section was blocked with 3% H2O2 for 3 minutes to
eliminate endogenous peroxidase. Sections were incu-
bated in biotinylated rabbit anti-immunoglobulin (Ig)
(1:200) and then in avidin-biotin-horseradish peroxidase
complex for 30 minutes each at room temperature. After
PBS washing, the reaction was visualized by the addition
of freshly prepared 3, 3-diaminobenzidine tetrahydro-
chloride (7.5 mg in 15 mL PBS with 15 L 30% H2O2)
and examined by light microscopy. Positive control tissue
for all antibodies was splenic tissue from mice injected
intravenously with lipopolysaccharide. Negative controls
were incubated with irrelevant antibodies of the same
strain and isotype as the primary antibody in use.
The number of macrophages, CD4- and CD8-positive
cells was quantitated in 10 nonoverlapping cortical fields
(400, measuring 0.075 mm2 each). Using image analysis,
the mean number of positive cells per interstitial field
was calculated for each section and expressed as cells
per mm2. For CD40, expression at 14 and 42 days after
adriamycin was compared between the three animal sub-
groups.
Staining for CD40L was attempted using the MR1
antibody, with a biotin-conjugated mouse antihamster
antibody as the secondary reagent (1:100, BD Biosci-
ences). Splenic tissue from lipopolysaccharide-treated
mice was used as a positive control tissue. Immunofluo-
rescent and enzymatic methodology were trialed in an
attempt to detect primary antibody binding.
Comparative expression of chemokine mRNA
Relative expression of the chemokines MCP-1 and
RANTES were compared by reverse-transcription poly-
merase chain reaction (RT-PCR). Cortical tissue from
the pole of each kidney was obtained at the time of
animal sacrifice and snap-frozen in liquid nitrogen prior
to storage at 	70C. Total cellular RNA was extracted
using TRIreagent (Sigma Chemical Co., St. Louis, MO,
USA), according to the guanidine thiocyanate/phenol/
chloroform method [14]. One microgram of isolated
RNA was reverse transcribed into complementary DNA
(cDNA) in a standardized reaction using the MuLV en-
zyme (2.5U/L) (Roche Molecular Systems, Branch-
burg, NJ, USA). For MCP-1 and RANTES, 50 ng of
cDNA was then amplified in a PCR reaction using the
thermostable DNA polymerase Taq (Roche Molecular
Systems). Twenty nanograms of cDNA was used for the
chosen housekeeping gene (18S RNA). The sequence
of the primers used for these experiments is shown in
Table 1. For each PCR reaction, the linear phase of PCR
amplification was determined prior to the final PCR of
the experimental samples. PCR products were measured
by densitometric analysis after ethidium bromide-aga-
rose gel electrophoresis using a gel documentation sys-
tem (Fluor-S; Bio-Rad, Hercules, CA, USA). The rela-
tive RNA expression for each sample was then calculated
by dividing the density of the chemokine RNA by the
amount of 18S RNA for each sample.
Statistical analysis
The results are expressed as mean SD, and statistical
significance of differences among groups was determined
by one-way analysis of variance (ANOVA). A P value
of less than 0.05 was considered statistically significant.
RESULTS
Functional and pathologic changes
All adriamycin-treated mice developed renal injury.
Body weight was reduced in both the adriamycin and
MR1  adriamycin groups. Kidneys of adriamycin-
treated mice were pale and atrophic, whereas those of
the MR1  adriamycin group were hypertrophied com-
pared to those of normal control. Proteinuria appeared
5 days after adriamycin administration, and remained at
similar levels throughout the study period, as evaluated
by urinalysis. Renal function at the end of experiment is
summarized in Table 2. Serum creatinine and creatinine
clearance were severely impaired in the adriamycin-
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Table 2. Comparison of functional markers of disease severity at 42 days after adriamycin
Normal Adriamycin alone MR1  adriamycin
(group 1) (group 2) (group 3)
Body weight g 24.41.6 18.61.8 20.63.0
Serum creatinine mmol/L 23.63.2 51.44.4 29.56.7b
Serum albumin g/L 27.63.1 23.73.1 23.11.4
Urinary protein mg/24 hours 0.70.2 4.30.8 1.80.6b
Urinary protein creatinine mg/mmol 0.30.2 3.30.8 1.40.6b
Creatinine clearance lL/min 824 352 754a
a P  0.01 vs. group 2
b P  0.05 vs. both groups 1 and 2
Table 3. Comparison of pathologic markers of disease severity at 42 days after adriamycin
Normal Adriamycin alone MR1  adriamycin
(group 1) (group 2) (group 3)
Glomerular changes
Glomerular surface area lm2 3292569 2463630 3142675a
Glomerular sclerosis % 0 30.27.2 20.14.7b
Number of nuclei per glomerulus 32.55.7 21.84.3 30.94.9a
Tubulointerstitial changes
Tubular diameter lm 37.35.7 66.313.7 42.56.9b
Tubular cell height lm 18.21.9 111.8 16.31.7b
Interstitial volume % 1.30.7 26.24.9 13.95.1b
aP  0.001 compared to group 2
bP  0.01 compared to groups 1 and 2
alone group, but with MR1 treatment were close to the
levels of normal mice. Proteinuria was improved with
MR1 treatment.
Histologic analysis showed that MR1 treatment sig-
nificantly reduced structural damage in adriamycin ne-
phropathy (Table 3 and Fig. 1). Glomeruli and tubules
were only mildly damaged at week 6 in the MR1 
adriamycin mice when compared with the adriamycin-
alone group. Glomerular surface area was significantly
reduced in the adriamycin-alone mice as a result of shrink-
age due to glomerulosclerosis, but there was no differ-
ence in glomerular size between MR1  adriamycin and
normal mice. There was much less glomerulosclerosis in
the MR1  adriamycin group when compared to the
adriamycin-alone group (P  0.01), as well as more nu-
clei per glomerular cross-section (P  0.001). Interstitial
expansion was severe in the adriamycin-alone mice, but
much less severe in the MR1  adriamycin group (P 
0.01). Tubular atrophy was significantly reduced by MR1
treatment in comparison with the adriamycin-alone mice
(Fig. 1).
CD40 expression
There was minimal expression of CD40 within the
normal kidney (Fig. 2A). Following adriamycin, there
was a progressive increase in CD40 expression within
the kidney (Fig. 2 B and C) that was greatest in areas
of glomerular and tubulointerstitial injury. Expression
of CD40 was predominantly glomerular and interstitial
at 14 days after adriamycin (Fig. 2B). CD40 expression
was extensive 42 days after adriamycin and present in
glomeruli, tubules, and the interstitium (Fig. 2C). Ex-
pression of CD40 in the kidney of the MR1  adriamy-
cin-treated animals occurred in a similar pattern but was
reduced in extent, in parallel with the reduction in patho-
logic injury.
Significant cell-associated CD40L was not detected in
splenic or kidney tissue of any mice by enzymatic or
fluorescent methods of detection (data not shown).
Number of interstitial mononuclear cells
Adriamycin nephrosis was associated with an intersti-
tial mononuclear cell infiltrate consisting of numerous
macrophages, CD4, and CD8 lymphocytes. The number
of infiltrating macrophages in mice with adriamycin ne-
phropathy was significantly reduced by MR1 treatment
(Figs. 3 and 4) at both 14 and 42 days. The number of
infiltrating CD4 and CD8 lymphocytes was reduced
at 14 days in the MR1  adriamycin group (Fig. 4A);
however, this result did not reach statistical significance
(P  0.06 for CD4 lymphocytes, P  0.3 for CD4
lymphocytes). At 42 days after adriamycin, there was no
significant difference in the number of CD4 or CD8
lymphocytes between the adriamycin-alone or MR1 
adriamycin groups (Fig. 4B).
Cortical chemokine expression
Adriamycin nephrosis was associated with signifi-
cantly increased relative cortical expression of MCP-1
and RANTES mRNA at the 42-day time point (Fig. 5).
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Fig. 1. Comparison of histologic changes in periodic acid-Schiff (PAS)-
stained sections at day 42 after adriamycin. Compared to the normal
kidney (A ), the adriamycin-alone group (B ) showed severe changes of
For both chemokines, MR1 treatment was associated
with significantly reduced expression at the 42-day time
point (P  0.01 for MCP-1 and P  0.05 for RANTES).
DISCUSSION
In this study, adriamycin nephropathy was associated
with progressive inducible expression of CD40 by both
parenchymal and infiltrating cells. Blockade of CD40-
CD40L interactions protected against structural and
functional injury in mice with established disease. MR1
treatment significantly reduced glomerular sclerosis, tu-
bular atrophy, and interstitial expansion and protected
against functional loss. In addition, MR1 treatment was
associated with a reduction of cortical proinflammatory
signals and reduced macrophage infiltration in the
cortex.
Previous investigators have shown that CD40L block-
ade protects against the initiation and progression of
renal disease in murine models of membranous and lupus
nephritis [8, 9, 15]. In both of these models of injury,
the effect of CD40L blockade was thought to be due
to impaired production of pathogenic antibodies by B
lymphocytes. In this study, we found that CD40L block-
ade significantly protected against renal inflammation
and injury in adriamycin nephrosis, a model in which
the initiation of injury is not antibody-dependent. Protec-
tion in adriamycin nephrosis was also seen when CD40L
blockade was started after glomerular injury was initi-
ated, suggesting a broader role for CD40-CD40L in the
pathogenesis of renal inflammation in this model.
Several possibilities exist to explain the reduction in
glomerular damage and tubulointerstitial inflammation and
injury in this model. One explanation is that blockade
may interfere with CD40L-dependent effects on T-lym-
phocyte antigen recognition. Interaction between CD40
expressed by an antigen-presenting cell with membrane-
associated CD40L on T lymphocytes is an important co-
stimulatory signal necessary for antigen recognition [16].
A number of experimental findings support the possibil-
ity that cognate T-cell responses contribute to inflamma-
tion in chronic renal diseases. In vitro stimulation studies
have demonstrated that tubular epithelial cells are capa-
ble of inducible expression of all the molecules necessary
for them to act as antigen-presenting cells [17, 18], al-
though the nature of potential antigen(s) involved in this
scenario remains unclear. We were unable to demon-
strate significant membrane-associated CD40L within
the kidney of mice with adriamycin nephrosis. Although
membrane-associated CD40L has been demonstrated on
glomerulosclerosis, tubular atrophy, and interstitial expansion. These
changes were significantly less in the MR1 adriamycin group (C ).
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Fig. 2. Immunoperoxidase staining of cortical CD40 expression in murine adriamycin nephrosis. In the normal kidney (A ), there was minimal
CD40 expression of CD40 within tubules and glomeruli (G). CD40 expression was significantly increased at 14 days and 42 days after adriamycin
(B and C ). At 14 days (B), this expression appeared largely confined to glomeruli (G) and the interstitium. At 42 days after adriamycin (C), there
was widespread expression of CD40 by glomerular cells, tubular cells, and cells of the expanded interstitium.
Fig. 3. Immunostaining for renal macrophages at day 42 after adriamycin. There was an extensive interstitial macrophage infiltrate in the adriamycin-
alone group (A ). The number of interstitial macrophages was reduced in the MR1  adriamycin group (B ).
infiltrating lymphocytes of rejecting renal allografts [19],
it has been difficult to demonstrate cells bearing CD40L
in chronic renal injury models [20]. Several possible ex-
planations exist for this finding. In vitro studies suggest
that surface expression of CD40L by T lymphocytes is
rapidly and transiently induced after activation [21, 22]
and declines to baseline levels after 48 hours, despite
ongoing activation. A further explanation is for the appar-
ent absence of membrane-associated CD40L is the possi-
bility that the soluble cytokine-like form of CD40L is
the predominant form in this model and exerts its effect
remotely by binding to CD40 in this model.
The protective effect of MR1 could also be explained
by its interference with CD40-dependent effects on in-
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Fig. 4. Comparison of the number of infiltrating mononuclear cells at 14 (A ) and 42 days (B ) after adriamycin. MR1 treatment was associated
with a significant reduction in the number of infiltrating macrophages. The number of infiltrating CD4 and CD8 cells was not statistically
different from the adriamycin-alone group. Bars represent mean values  standard deviation. **P  0.01 vs. adriamycin-alone group.
Fig. 5. Relative cortical mRNA expression of the chemokines monocyte chemoattractant protein (MCP-1) (A ) and regulated on activation normal
T cell expressed and secreted (RANTES) (B ). Adriamycin nephrosis was associated with significantly increased cortical expression of MCP-1 and
RANTES at the 42-day time point. MR1 treatment was associated with significantly reduced expression of these chemokines at this time point.
Bars represent mean values  standard deviation. *P  0.05; **P  0.01 vs. control group.
flammation. In this experiment, we found that MR1
treatment in adriamycin nephropathy was associated
with a significant reduction in the number of infiltrating
macrophages. Treatment was also associated with a trend
toward a reduction in the numbers of infiltrating CD4
and CD8 lymphocytes at the day 14 time point. The
lack of statistical significance for the latter result may
partially be explained by a 
 effect. A possible explana-
tion for this powerful anti-inflammatory effect may be an
attenuated production of the chemokines and adhesion
molecules necessary for interstitial inflammation to oc-
cur. In vitro ligation of CD40 on renal tubular epithelial
cells and monocytes induces the production of multiple
chemokines and adhesion molecules [1, 5, 6]. It is there-
fore possible that the reduction in inflammation seen
with MR1 treatment in adriamycin nephropathy is due
to an inhibition of interaction between CD40L (ex-
pressed on or secreted by mononuclear cells) and CD40
(abundantly expressed on parenchymal and interstitial
cells in this model). In support of this hypothesis is the
finding in the current experiments that MR1 treatment
was associated with significant reductions in the expres-
sion of MCP-1 and RANTES mRNA at the 42-day time
point (Fig. 5). Both of these chemokines have previously
been shown to be produced by renal tubular cells in
response to CD40 ligation [5].
CONCLUSION
Blockade of CD40-CD40L interactions in established
murine adriamycin nephrosis attenuates interstitial in-
flammation and protects against parenchymal injury.
These results have potential therapeutic relevance for
the treatment of renal inflammation in human chronic
renal diseases if agents can be developed that safely
disrupt CD40-CD40L interactions.
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